This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://linked.opendata.cz/resource/drugbank/drug/DB00856/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00856/identifier/kegg-compound/
n13http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00856/identifier/pubchem-compound/
n21http://linked.opendata.cz/resource/drugbank/mixture/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00856/identifier/pubchem-substance/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00856/identifier/drugbank/
n18http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://www.drugs.com/mtm/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00856/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00856
rdf:type
n3:Drug
n3:description
A centrally acting muscle relaxant. Its mode of action is unknown. Chlorphenesin is not available in the United States.
n3:generalReferences
# Malley A, Baecher L: Inhibition of histamine and SRS-A from monkey lung tissue by chlorophenesin. J Immunol. 1971 Aug;107(2):586-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4105542 # Kurachi M, Aihara H: Effect of a muscle relaxant, chlorphenesin carbamate, on the spinal neurons of rats. Jpn J Pharmacol. 1984 Sep;36(1):7-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6503049 # Dalessio DJ: Medical treatment of the major neuralgias. Semin Neurol. 1988 Dec;8(4):286-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3074423
n3:group
approved withdrawn
n3:halfLife
2.3-5 hours
n3:indication
Used, along with rest and physical therapy, to treat injuries and other painful muscular conditions. Investigated for use in trigeminal neuralgia (tic douloureux), a neuropathic disorder characterized by severe facial pain. Was investigated as a modulator of histamine release.
n3:manufacturer
n13:271B4E7F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00856 n18:DB00856
dcterms:title
Chlorphenesin
adms:identifier
n6:DB00856 n9:7411 n10:7697 n11:46504714 n12:C07928 n19:PA164784022
n3:mechanismOfAction
The mechanism of action of chlorphenesin is not well defined, and its effects are measured mainly by subjective responses. It is known that chlorphenesin acts in the central nervous system (CNS) rather than directly on skeletal muscle.
n3:synonym
3-(4-Chlorophenoxy)-1,2-propanediol Chlorphenesinum Chlorphenesin Chlorphénésine Glycerol alpha-P-chlorophenyl ether Clorfenesina 3-(P-Chlorophenoxy)-1,2-propanediol P-Chlorophenyl-alpha-glyceryl ether 3-(P-Chlorophenoxy)propane-1,2-diol
n3:toxicity
Symptoms of a chlorphenesin overdose include drowsiness and nausea.
n3:mixture
n21:271B4E7E-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Parker, H.E.; U S . Patent 3,214,336; October 26, 1965; assigned to The Upjohn Company. Collins, R.J. and Matthews, R.J.; US. Patent 3,161,567; December 15, 1964; assigned to The Upjohn Company.
n14:hasConcept
n15:M0004189
foaf:page
n8:chlorphenesin.html
n3:IUPAC-Name
n4:271B4E84-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4E8A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4E89-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4E86-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4E87-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4E88-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4E82-363D-11E5-9242-09173F13E4C5 n4:271B4E9A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4E80-363D-11E5-9242-09173F13E4C5 n4:271B4E83-363D-11E5-9242-09173F13E4C5 n4:271B4E9C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4E81-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:D01AE07
n3:H-Bond-Acceptor-Count
n4:271B4E90-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4E91-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4E8B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4E8C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4E8E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4E8D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4E8F-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid and complete.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
104-29-0
n3:category
n3:Bioavailability
n4:271B4E96-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4E98-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4E99-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4E9B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4E95-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4E94-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4E97-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4E85-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4E92-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4E93-363D-11E5-9242-09173F13E4C5